Bulevirtide 2 mg and Brelovitug - 300 mg

Drug identity checked against registry records

Also recorded as Hepcludex

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908MIRMPhase 3Recruiting2027-06-30Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.